Results 131 to 140 of about 243,350 (258)

Clonal expansion and phenotypic alterations of TCR Vβ3⁺ T cells in juvenile-onset recurrent respiratory papillomatosis: implications for tumor-associated immunity and chemokine-mediated T-cell trafficking. [PDF]

J Virol
Li S, Wang W, Peng Y, Wang G, Xi Y, Wang S, Zhao J, Zhang F, Wang H, Li H, Duan Q, Long T, Gui J, Ni X, Zhang J.   +14 more
europepmc   +1 more source

Targeted Delivery of Indole‐3‐Pyruvic Acid Suppresses Macrophage Ferroptosis to Enhance CD8+ T Cell‐Mediated Immunotherapy Response in Bladder Cancer

Advanced Science, EarlyView.
A microbiota‐derived metabolite, indole‐3‐pyruvic acid, suppresses macrophage ferroptosis through the AHR–NF‐κB–SLC7A11 axis. This preserves CD8+ T cell function in bladder cancer. Macrophage‐targeted nanoparticles enhance indole‐3‐pyruvic acid delivery and overcome resistance to PD‐1 blockade.
Jianwen Lao, Xinhao Yuan, Shuai Liang, Kai Deng, Daqin Wu, Longhao Xu, Kun Zheng, Yi Lin, Peicong Cai, Haoran Zheng, Junyu Chen, Mingli Luo, Yan Chen, Xiong Chen, Chunhui Wang, Wenlong Zhong   +15 more
wiley   +1 more source

Lymphocyte subsets in untreated thalassemia patients: differences by genotype and age. [PDF]

Front Immunol
Zhao R, Yao X, Feng S, Hu P, Zou Y, Yang Z, Zhang J, Guan X, Zhang C, Wang Z, Zhang J, Li Z, Wang Y.   +12 more
europepmc   +1 more source

Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress

Advanced Science, EarlyView.
Working model of SLC44A2‐mediated maintenance of pDC homeostasis. This model illustrates two central mechanisms by which SLC44A2 regulates pDC homeostasis: (1) SLC44A2 limits IFN‐I production by exporting amino acids (T, N, Q), thereby preventing spontaneous pDC activation.
Ruiqun Chen, Tao Wu, Zhen Shi, Ravi Kumar Verma, Linlin Sheng, Lei Tao, Mingming Yang, Yuchen Wang, Conggang Zhang, Hao Fan, Li Wu, Ligong Chen   +11 more
wiley   +1 more source

Different <i>SF3B1</i> Mutation Hotspots Show Hematopoietic Lineage-Specific VAF Patterns and Correlate with Distinct Genetic and Prognostic Profiles in Patients with Myeloid Neoplasms. [PDF]

Cancers (Basel)
Calvete O, Mestre J, Zamora L, Chaparro-González L, Ruiz Pérez-Hita L, Torres-Esquius S, Montoro MJ, Xicoy B, Solé F.   +8 more
europepmc   +1 more source

Engineering Human Donor Derived Germinal Center‐Like Organoids (GCLOs) for Studying Immune Response to Vaccination

Advanced Science, EarlyView.
We bioengineered a new approach methodology of generating Germinal Center Organoids that self‐organize from human blood‐derived immune cells. These immune organoids reproduce key features of humoral immunity, IgG production, and plasmablast emergence.
Bhumi Suthar, Carlos Gomez, Giancarlo Asencio, Suresh Pallikkuth, Ashutosh Agarwal   +4 more
wiley   +1 more source

Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts. [PDF]

Oncoimmunology
Lécuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Huppé T, Emile JF, Bibeau F, Taïeb J, Derangère V, Lepage C, Ghiringhelli F.   +13 more
europepmc   +1 more source

Ultrasound‐Recharged Sub‐Nanometer Palladium Catalysts for on‐Demand and Self‐Terminating Bioorthogonal Prodrug Activation in Cancer Therapy

Advanced Science, EarlyView.
Safe and precise bioorthogonal therapy of tumors was achieved by an ultrasound‐responsive heterostructured nanoreactor with on‐demand catalytic activity. Under piezoelectric catalysis, the system undergoes reversible Pd2+/Pd0 redox cycling, concurrently enabling spatiotemporally controlled prodrug activation and self‐terminating catalytic dose ...
Daqing Xia, Lei Liu, Shuang Jin, Guangxu Fang, Chang Yu, Yunyun Wu, Lunli Xiang, Hongrui Zhu, Zhenqiang Wang, Jixi Zhang   +9 more
wiley   +1 more source

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated. [PDF]

J Exp Med
Eken A, Johnson SA, Erdem S, Hsieh EWY.
europepmc   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Advanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai, Minyu Chen, Yinghan Wang, Wei Chen, Junhang Luo, Yanping Liang   +16 more
wiley   +1 more source